Clinical trials: Patients With Advanced Solid Tumors
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or…
- Trial name
- NCT06521554
- Testing
- NVL-330
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Nuvalent Inc.
Advanced or Metastatic Solid Malignancies
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
- Trial name
- NCT04887870
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 49 people
- Sponsor
- Mirati Therapeutics Inc.
Neoplasms
A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor
Tafetinib is an oral multitargeted tyrosine kinase inhibitor that inhibits Vascular Endothelial Growth Factor Receptor (VEGFR). This phase I trial was conducted to evaluate the pharmacokinetics (PK), safety, and preliminary…
- Trial name
- NCT02717741
- Testing
- tafetinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Advanced Solid Tumors
Study of ZGGS15 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, Phase 1 clinical study of ZGGS15 for the treatment of patients with advanced solid tumors.
- Trial name
- NCT05864573
- Testing
- ZGGS15
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Solid Tumor and Lymphoma
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the…
- Trial name
- NCT07333469
- Testing
- HX111 for injection
- Volunteers
- 70 people
- Sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Metastatic Solid Neoplasm, Lymphoma
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
This Phase 1, open-label, multicenter, 2-arm study was designed to evaluate SYNB1891 when administered either as monotherapy (Arm 1) or in combination with atezolizumab (Arm 2) in participants with advanced/metastatic solid…
- Trial name
- NCT04167137
- Testing
- SYNB1891, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Synlogic
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Advanced Solid Tumors, Gastric Cancer
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT02318329
- Testing
- FPA144
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Five Prime Therapeutics, Inc.
Advanced Cancer, Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
This study is a first-in-human, multicenter, open-label, nonrandomized, dose-escalation trial to be conducted in 2 sequential parts: Part A (Dose Escalation) in subjects with advanced malignancies Part B (Dose Confirmation) in…
- Trial name
- NCT02797795
- Testing
- NEV801
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Neovia Oncology Ltd.
Advanced Solid Tumors
HS-20117-2 Injection in Patients With Advanced Solid Tumors
This trial is a multicenter, open-label, Phase I clinical study designed to evaluate the pharmacokinetics, safety, and tolerability of HS-20117-2 in patients with advanced solid tumors.
- Trial name
- NCT07775703
- Testing
- HS-20117-2 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hansoh BioMedical R&D Company
Solid Tumor
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT06046742
- Testing
- M1-c6v1
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard…
- Trial name
- NCT07222969
- Testing
- VIB305 for Injection
- Where
- 2 sites in Australia, China
- Volunteers
- 146 people
- Sponsor
- Vibrant Sciences Limited
Neoplasms，Non-Small Cell Lung Cancer
Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer
The purpose of this study is to assess the pharmacokinetics，safety and tolerability of Hemay020 and to determine the recommended dose for future Phase II study as well as to obtain preliminary information on the efficacy of…
- Trial name
- NCT02467569
- Testing
- Hemay020
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Cancer, Pancreatic Cancer
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in…
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
- Trial name
- NCT03678883
- Testing
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 350 people
- Sponsor
- Actuate Therapeutics Inc.
Platinum-resistant Ovarian Cancer, Testicular Cancer
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with…
- Conditions
- Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
- Trial name
- NCT06515613
- Testing
- CTIM-76
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Context Therapeutics Inc.
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and…
- Trial name
- NCT04649385
- Testing
- BGB-15025, Tislelizumab, Carboplatin
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 157 people
- Sponsor
- BeiGene
Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced…
- Trial name
- NCT06234397
- Testing
- BH3120, pembrolizumab
- Where
- 10 sites in United States, South Korea
- Volunteers
- 216 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Solid Tumor, Adult, Relapsed Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of…
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05662397
- Testing
- HST-1011, Cemiplimab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- HotSpot Therapeutics, Inc
Cancer, Advanced Solid Malignancies
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.
- Trial name
- NCT01213160
- Testing
- AZD4547
- Where
- 3 sites in Japan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.